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SUMMARY 
 
The global epidemic of obesity, that is rapidly expanding in both developed and 
developing countries, is becoming a major public health problem worldwide. 
According to a recent report by the World Health Organization, there are > 1 billion 
overweight adults worldwide and at least 300 million of these individuals are 
clinically obese. Approximately two-thirds of US adults and the majority of the rest 
of the Western adult population are overweight or obese (defined as BMI ≥ 30 
Kg/m2) (1). 
The rise in the incidence of obesity has led to a major interest in the biology of 
adipose tissue. Historically, adipose tissue has been viewed as a passive fat storage 
and a body´s insulator. However, in recent years, it has been recognized to have an 
active role in the development and maintenance of obesity. 
Adipose tissue is an active endocrine organ capable of  releasing a variety of 
hormones and bioactive molecules, called adipocytokines, which are important in 
metabolic regulation. 
Glucose metabolism is essential to the adipocyte for energy supply and for 
maintaining normal esterification rate of free fatty acids (FFA). 
Evidence from several studies indicates that obesity is closely associated with an 
increased risk of type 2 diabetes, and the term “diabesity” has been coined to suggest 
a single problem. A unifying hypothesis to explained these metabolic disorders is 
insulin resistance (IR). 
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It was seen that a slight weight reduction, even if weight loss of 5%, modifies risk 
factors such as hyperinsulinemia, hypertension and diabetes (2), and decreases the 
risk for type 2 diabetes (3). 
However, conventional treatment of obesity, that includes medical therapies such as 
dietary interventions, physical activity, behavioural therapy and drug therapy, 
unfortunately have not resulted in significant improvement among morbidly obese 
patients, especially because they are ineffective in the long term. 
For this reason, over the past decade, bariatric surgery has gained increasing 
acceptance as the most effective treatment for morbid obesity and the long-term 
results regarding weight loss and improvement of obesity-related comorbidities have 
been well established (4). In obese patients with type 2 diabetes, bariatric surgery is 
associated with high rates of diabetes remission (5). 
In the present study we were able to investigate changes in adipose tissue glucose 
uptake pre-operatively and after bariatric surgery using positron emission 
tomography (PET), the gold standard method that permits non- invasive measurement 
of regional glucose uptake, in vivo, in human.  
The aim of the present study is to examine the effect of bariatric surgery on 
subcutaneous adipose tissue glucose uptake and insulin sensitivity in severely obese 
patients and to evaluate if changes in adipose tissue metabolism are related with the 
remission of type 2 diabetes.  
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INTRODUCTION 
Obesity 
Obesity, that can be defined as an excess of body fat mass in both developed and 
developing countries, is becoming a major public health problem worldwide. 
According to a recent report by the World Health Organization (WHO), there are > 1 
billion overweight adults worldwide and at least 300 million of these individuals are 
clinically obese. Approximately two-thirds of US adults and the majority of the rest 
of the Western adult population are overweight or obese (defined as BMI ≥ 30 
Kg/m2).  
Both the BMI and the prevalence of obesity have increased in Finland during the last 
two decades. In the year 2002 the average BMI among working men was 27 kg/m2 
and among working women 25.9 kg/m2. At least 66 % of men and 49 % of women 
were slightly overweight (BMI ≥ 25 kg/m2) and one fifth were remarkable obese 
(BMI ≥ 25 kg/m2) (3). In the future overweight and obesity rates will increase 
substantially (4) contributing to the increase in number of people with diabetes by 
more than 2.5-fold, from 84 million in 1995 to 228 million in 2025 in developing 
world (5) .  
To estimate the degree of obesity the body mass index (BMI) is used. It may be 
calculated by dividing the weight in kilograms by height in meters squared Kg/ m2) . 
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Normal weight is defined as BMI < 25 Kg/m2, because BMI higher than this is 
associated in increased risk of having many diseases (4). Mild obesity is defined as 
BMI 25.0-29.9 Kg/m2. Corresponding values for moderate and serious obesity are 
30.0-34.9 Kg/m2 and 35.0-39.9 Kg/m2. Morbid obesity is defined as BMI > 39.9 
Kg/m2 or more. 
The high prevalence of this condition may also have serious implications for health 
care cost. In fact, obesity is associated with an increased risk for the development of 
many diseases that lead to increased morbidity and mortality, among them type 2 
diabetes mellitus (T2DM), dyslipidemia, hypertension, heart disease, stroke, 
obstructive sleep apnea, gout, fatty liver, gallstones, orthopaedic problems leading to 
accelerated osteoarthritis and low back conditions, depression, asthma and some 
forms of cancer (postmenopausal breast cancer, cervical cancer, colon cancer and 
kidney cancer) (7). 
Obesity is associated with defects such as altered glucose metabolism and insulin 
resistance. At the cellular level, defects in glucose transport and phosphorylation 
contribute to insulin resistance in obesity (8). Skeletal muscle is an important site for 
insulin-mediated glucose utilization (9). Defects in the translocation and function of 
glucose transporter protein 4 (GLUT4) in skeletal muscle and intracellular 
phosphorylation of glucose have been observed in obesity (10-11). 
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Liver is another target organ of insulin action. Adipose tissue is not only an important 
site of lipid storage but also an insulin-sensitive tissue needed in glucose and fatty 
acid metabolism. In obesity, the insulin action on metabolism is impaired in adipose 
tissue (12-14).  
Most of the whole body glucose uptake is non-insulin-mediated and occurs outside 
skeletal muscle, mainly in the central nervous system (9). However, the insulin-
regulated GLUT4 is also expressed in the hypothalamus (15). 
When 3H-labelled deoxyglucose is used to quantify the effects of insulin on glucose 
uptake and metabolism in animal studies, hyperinsulinaemia has been shown to 
enhance both skeletal muscle and adipose tissue glucose uptake several-fold (16). 
Kraegan et al (17) performed similar studies during euglycaemia, and the metabolic 
index of glucose increased 10-fold in skeletal muscle and twofold in adipose tissue 
(17). The compound 2-18Ffluoro-2-deoxy-D-glucose (FDG) is a positron-emitting 
glucose analogue with high specific radioactivity. FDG is taken up by tissues and 
phosphorylated as glucose, but is only slowly and minimally metabolized thereafter 
(10, 18). FDG lacks the 2-hydroxyl group and, therefore, cannot be further 
metabolized via the glycolytic pathway. When studies are performed under steady-
state conditions, tissue-specific glucose uptake rates can be calculated by multiplying 
the fractional FDG uptake rate by the plasma glucose concentration, and dividing this 
by a lumped constant (LC). This accounts for differences between tissue glucose and 
FDG uptake and phosphorylation (19-20). 
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Evidence from several studies indicates that obesity is closely associated with an 
increased risk of type 2 diabetes (6), and the term “diabesity” has been coined to 
suggest a single problem (7-8). A unifying hypothesis to explained these metabolic 
disorders is insulin resistance (IR). 
 
Insulin resistance (IR) 
Insulin resistance (IR) can be defined as an impaired biological response to the 
metabolic and/or mitogenic effects of either exogenous or endogenous insulin.  
As skeletal muscle accounting for 70-80% of the whole body glucose uptake during 
insulin stimulation, whole  body insulin resistance  reflects primarily skeletal muscle 
insulin resistance (Nuutila et al. 1992). 
Insulin resistance in obese and type 2 diabetes patients is characterized by decreased 
insulin-stimulated glucose transport and metabolism in adipocytes and skeletal 
muscle (Ciaraldi et al. 1982, Kashiwagi et al. 1983; Garvey et al. 1991; Reaven 
1995). 
In adipose tissue of obese and type 2 diabetes patients  insulin binding to its receptors 
is not changed (Bolinder et al. 1996) but receptor phosphorylation and tyrosine kinase 
activity are reduced (Hotamisligil et al. 1994).  
Furthermore, in these patients, insulin receptor substrate-1 (IRS-1) expression is 
reduced, resulting in decreased IRS-1 associated PI3K activity, and IRS-2 becomes 
the main docking protein for PI3K (Rondinone et al. 1997; Kahn & Flier 2000). 
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Adipose tissue has a central role in maintaining normal insulin sensitivity (Frayn 
2002) and this is demonstrated by the fact that both excess of adipose tissue 
(Bogardus et al. 1985) and deficiency of adipose tissue in lipodystrophy or 
lipoatrophy (Ganda 2000) are associated with insulin resistance. 
Moreover, this is also demonstrated in studies in transgenic mice (Mauvais –Jarvis et 
al. 2002). In insulin resistant condition, expression of GLUT4 gene is regulated 
differently in muscle and in adipose tissue. In obese or type 2 diabetes patients, 
adipose tissue GLUT4 expression is decreased (Garvey et al. 1988). 
It has been theorized that the “Randle cycle”,  also known as the glucose fatty-acid 
cycle, play a role in explaining obesity-related insulin resistance. (Bevilacqua S, 
Buzzigoli G, Bonadonna R, et al (1990)., Shuldiner AR, McLenithan JC (2004), 
Delarue J, Magnan C (2007). "Free fatty acids and insulin resistance". Current 
opinion in clinical nutrition and metabolic care.).The Randle Cycle is a metabolic 
process in which increased adiposity, especially in the visceral depot, leads to 
increased FFA flux and inhibition of insulin action (Fig. 1).  
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Fig. 1 (Figure based on Randle et al., 1963 and adapted from Hue & Taegtmeyer, 
2009). Randle’s “glucose-fatty acid cycle”: a reciprocal control (hormone 
independent) between glucose and fatty acid metabolism depicted by black arrows. 
Red arrows represent the control operated by insulin: glucose uptake stimulation and 
lipolysis inhibition. FA-CoA, Fatty acid acyl-CoA; G3P, L-glycerol-3-phosphate; 
TAG, triacylglycerol; Pyr, pyruvate. 
 
Glucose metabolism 
Glucose is taken up by tissue by a mechanism based on mass action or actively by 
specific glucose transporter molecules (GLUT) on the cell membrane. 
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 In healthy subjects acute hyperglycemia suppresses hepatic glucose production and 
increases peripheral glucose uptake (DeFronzo t al. 1985; Hawkins et al. 2002). 
GLUT molecules are located in cytosol as vacuoles in the resting phase and are 
transported to the cell membrane to meet the need of accelerated glucose transport 
into the cell (Fig. 2). At basal state, GLUT-cycle is minor. In mature adipocytes, 
glucose uptake is increased 20-to 30-fold by insulin and several glucose transporter 
proteins are responsible for active glucose transport into the tissues. GLUT1 is 
abundant in adipose tissue as well as in skeletal muscle and is principally responsible 
for facilitated glucose transport in the basal state but can be activated as well by 
insulin (Kahn 1992). GLUT4 is the most important insulin-responsive glucose 
transporter located in skeletal muscle, adipose tissue and the hypothalamus (James et 
al.1998; Livingstone et al.1995). Glucose transport stimulate by insulin reaches its 
maximum in 10 minutes, whereafter it remains at maximal level as long as insulin 
stimulation continues. Insulin stimulates glucose transporter, either increasing the rate 
of GLUT translocation (Cushamn &Wardzala 1980) or the number of GLUT proteins 
on adipocyte cell membrane (Cusin et al. 990). For the stimulation of glucose 
transport by insulin, the activation of phosphoinositide-3 kinase (PI3K;downstream 
of receptor phosphorylation and activation of insulin receptor substrates (IRS) in the 
insulin signaling pathway) is necessary in both adipocytes and muscle cells 
(Shepherd & Kahn 1999). 
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After entering the cell, glucose is rapidly phosphorylated by herokinase (Katzen et al. 
1970).Glucose-6- phosphate is further stored as glycogen or converted to pyruvate 
(glycolysis). Pyruvate is oxidized to acetyl coenzyme A (acetylCoA) by pyruvate 
dehydrogenase, and further oxidized in mitochondrion to produce carbon dioxide and 
water as end products. Glycogen can also be formed via futile cycling of glucose. 
This means that glucose-6-phosphate is first metabolized until pyruvate but returns to 
glycogen for storage. In liver and skeletal muscle glucose futile cycling has an 
important regulatory role (Vranic et al. 1985).Whether futile glucose cycling takes 
place in adipocytes where glycogen content is considered minor is not known. 
In adipocytes, glucose is able to enter several metabolic routes. After converting 
glucose-6-phosphate to glycerol 3-phosphate (glycerol 3-P), oxidation in the Krebs 
cycle, production of lactate or conversion to triglycerides may occur. Glycerol 3-P is 
a key metabolite of glucose conversion to triglycerides because it can be combined 
with intracellular free fatty acids (FFA). In vivo data gathered with microdialysis 
support the view that adipose tissuer is an important source of lactate (Jansson et al. 
1990). Lactate is either used as fuel in other tissues such as the heart and skeletal 
muscle, or oxidized back to pyruvate primarily in the liver. 
Adipose tissue glucose metabolism is highly regulated by insulin. In vitro, insulin 
stimulates glucose uptake into adipocytes (Green & Newsholme 1979). 
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When [3H]-labelled deoxyglucose is used to quantitate the effects of insulin on 
glucose uptake and metabolism in animals, hyperinsulinemia enhances both skeletal 
muscle and adipose tissue glucose uptake several fold (Hom & Goodner 1984; 
Kraegen et al. 1985). Insulin stimulation derived by hyperinsulinemic euglycemic 
clamp decreases extracellular glucose concentration in subcutaneous adipose tissue 
(Hagstrom-Toft et al. 1992), indicating facilitated glucose uptake by the tissue. In 
addition to facilitated glucose transport, insulin is able to regulate glycolytic enzymes 
such as herokinase and pyruvate dehydrogenase (Mandarino et al. 1987) which 
accelerate glycolysis. Concentrations of lactate and pyruvate increase in extracellular 
fluid of adipose tissue by insulin stimulation (Hagstrom-Toft et al. 1992).  
Insulin receptor expression is higher in omental than in subcutaneous adipocytes, but 
omental insulin receptors seem to transmit insulin signal less efficiently than 
subcutaneous receptors (Lefebvre et al. 1998). Moreover, omental adipocytes express 
twofold decreased GLUT4 mRNA when compared with subcutaneous adipocytes 
(Lefebvre et al. 1998). 
Higher activity has been found in abdominal compared with femoral fat triglycerides 
four hours after oral administration of  U-14C-glucose (Mǻrin et al. 1990). 
Radioactive label in triglycerides indirectly reflects glucose uptake in adipose tissue. 
Of the glucose taken up by adipose tissue, 80% is suggered to be converted to lactate 
in vitro (Mǻrin et al. 1990) and released to circulation (Jansson et al. 1990; Jansson et 
al. 1994).  
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In vivo studies suggest that only 13% of the glucose uptake in adipose tissue is 
converted to lactate (Frayn et al. 1989). Lactate release is not different in various 
subcutaneous regions nor are there differences in lactate release between obese and 
nonobese subjects in the fasting state (Jansson et al. 1994). 
 
 
Fig. 2 Glucose metabolism in adipose tissue 
 
Effect of obesity on adipose tissue metabolism 
Several studies have shown that adipose tissue is linked to insulin resistance 
(Ronnemaa et al. 1997; Ross et al.2002). In obesity the insulin action on metabolism 
is impaired in adipose tissue (Bolinder et al. 1986). 
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The insulin receptor density is decreased (Pedersen et al. 1982) and the glucose 
transport is less effective for a reduced number of glucose transporters in the 
intracellular pool (Hissin et al. 1982). Insulin signaling in adipose tissue seems to be 
crucial for development of obesity because adipose tissue selective insulin receptor 
knockout in mice (FIRKO-mice) protects against obesity and obesity-related glucose 
intolerance (Bluher et al. 2002). 
Studies regarding the effects of obesity on adipose tissue glucose metabolism in vivo 
provided controversial results. When radioactive U- [14C]glucose was given with 
glucose both intravenously (Bjorntorp et al. 1971) or orally (Marian et al. 1987), its 
incorporation into subcutaneous adipose tissue was one to four % of given glucose il 
lean subjects, and the incorporation was increased in obese patients (Bjorntorp et al. 
1971; Marin et al. 1987). Coppack et al. (1996) studied  adipose tissue glucose uptake 
using A-V technique and they did not found difference in adipose tissue glucose 
uptake between lean and obese individuals.  
 
Treatment of obesity 
Insulin resistance improves with reduction in obesity, but the treatment of obesity is 
not so simple as in theory (10). Traditionally, treatment of obesity includes  medical 
therapies such as dietary interventions, physical activity and behavioural therapy. 
Even modest weight loss of 5% alleviates hyperinsulinemia, hypertension and 
diabetes (Kopelman 2000), and decreases the risk for type2 diabetes (Tuomilehto et 
al. 2001) .  
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However, these kind of treatment were often unsatisfactory and more than 90% of 
individuals who lose weight return later to their original weight. During dietary 
interventions, the quality of nutrients is important for losing weight and maintain the 
lower weight. This may be due to the fact that fat has a weak satiating capacity when 
compared with carbohydrates, and high-fat foods predispose to overeating (Lawton et 
al. 1993).  
A change in the type of dietary fat consumed might have beneficial effects in curbing 
weight gain in men consuming relatively high-.fat diets, because postprandial fat 
oxidation rates are higher after high monounsaturated (from extra virgin olive oil), 
rather than saturated fat (from cream) meals (Piers et al. 2002). However, after six, 12 
or18 months on fat-restricted diets, no significantly different results could be 
observed except for total cholesterol concentration when compared with normal-fat 
including diets (Pirozzo et al. 2002). Fish oil in patients with type2 diabetes does not 
have a significant effect on fasting glucose, HbA1C,total or HDL cholesterol, but 
decreases triglycerides and elevates LDL cholesterol if the patient was 
hypertriglycerinemic at the beginning of the trials (Farmer et al. 2002). A 
carbohydrate-restricted diet (8% carbohydrate) reduces fat mass and increases lean 
body mass in normal weight men, which may be partially mediated by the reduction 
in circulating insulin concentrations (Volek et al. 2002). On a carbohydrate-restricted 
diet, 70% of the variability in fat loss is accounted for by the decrease in serum 
insulin concentrations (Volek et al. 2002).   
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Physical activity represents 20-50% of total energy expenditure. A combination of 
diet and exercise is more effective in weight loss than diet alone (Skender et al. 
1996). Any exercise is effective for weight loss: long-term low-intensity exercise 
(e.g. walking, cycling) is as effective as high-intensity activities (Despres & lamarche 
1994). Physical activity increases GLUT4 concentrations and insulin sensitivity in 
skeletal muscle in insulin resistant subjects and in patients with type 2 diabetes 
(Goodyear &Kahn 1998). Adipocytes from trained rats have a higher content of 
GLUT4 and a higher insulin-stimulated glucose transport in vivo than from 
nontrained rats (Stallknecht et al. 1993). In human adipocytes from trained subjects, 
insulin-stimulated 14Cglucose uptake in vivo is higher than from sedentary subjects 
(Rodnick et al. 1987). Training enhances insulin-sensitivity of glucose uptake in vivo 
both in subcutaneous and intra-abdominal adipose tissue (Enevoldsen et al. 2000), as 
well as insulin sensitivity of lipolysis (Stallknecht et al. 2000). 
Behavior therapy is also important in treatment of obesity. It includes advice on 
eating behaviour, recording of food intake, recognition of cues to overeating, realistic 
weight loss goals, and practical advice how to go on after failing. 
Drug therapy can be used added to help but should not given alone. Drug therapy is 
considered if BMI is over 30 kg/m2 and diet and physical activity and behaviour 
modification have failed, or if at BMI more than 25 Kg/ m2  comorbidities persist 
despite other obesity treatments (Bjorntorp 1997a). 
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Sibutramine and orlistat are able to achieve weight loss of >10% in about one-third of 
cases, when combined with appropriate dietary and lifestyle advice (Heymsfield et al. 
2000). Sibutramine is a serotonin and noradrenergic re-uptake inhibitor which 
induces weight loss by enhancing satiety and energy expenditure. Sibutramine 
produces weight loss which has been shown to be maintained up to one year 
(McNulty et al. 2003). Orlistat is a lipase inhibitor, leading to inhibition of dietary fat 
absorption by ˜30% (Hartmann et al.1993).When orlistat is combined with a 
hypocaloric diet, it produces and maintains clinically meaningful weight loss 
(Davidson et al. 1999). It also reduces WHR, improves glycemic control and 
cardiovascular risk factor profiles in overweight patients with type 2 diabetes (Broom 
et al.2002). In the future, β3-Adrenergic receptor agonist may provide another choice 
for the treatment of obesity. β3-Adrenergic receptor are expressed almost exclusively 
in fat; β3-Adrenergic agonist activate brown adipose thermogenesis and increase 
whole body energy expenditure in rodents (Arch et al. 1984). Humans and rodents 
have been treated with β3-Adrenergic agonist (de Souza et al.1997; Weyer et al. 1998) 
resulting in enhancement of both whole body glucose uptake and suppression of 
hepatic glucose production, as well as increased glucose uptake in adipose tissue (de 
Souza et al.1997). 
Over the past decade , bariatric surgery has gained increasing acceptance as a 
treatment for severe obesity and co-morbid diseases among patients who have failed 
conventional dietary or behavioural interventions.  
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In fact, surgical treatment is considered to be more effective than conservative treatment 
for morbid obesity (BMI ≥ 40 kg/m2) and co-morbid diseases and the long-term results 
regarding weight loss and has also beneficial effects on co-morbid diseases (21). 
Furthermore, in obese patients with type 2 diabetes, bariatric surgery is associated with 
high rates of diabetes remission (22). 
Two recently published, long-term follow-up studies indicate that surgical treatment is 
more effective to decrease mortality among morbidly obese patients compared to 
conventional treatment modalities (23;24).  
The most used surgical technique in the world is gastric bypass  (RYGB ) (Fig. 3), 
comprising over 65 % of all bariatric procedures over half of them done by using 
laparoscopy (24)]. In this procedure a pouch of ~30 ml is formed from the upper part of 
the stomach, in which small intestine is connected. 150 cm away from this connection of 
the small intestine (so-called efferent intestinal limb) and gastric pouch, a part of the small 
intestine (so-called afferent intestinal limb) is connected. This afferent limb of intestine 
conducts bile and pancreatic juices. There are two stapling techniques that can be used to 
connect the anastomosis between gastric pouch and the efferent limb of intestine: linear 
stapling and circular stapling. Both techniques are in use and the choice of technique 
depends mostly on the preference of the operating surgeon.  
21 
 
 
 
Fig. 3 Roux-en Y Gastric Bypass Surgery . 
Gastric bypass (GS) restricts food intake and leads to a mild malabsorptive state due to 
partial (150 cm) duodenal bypass. In addition there are changes in endocrine functions due 
to changes in secretion of hormones (26). The mean percent of excessive weight loss in 10 
year-follow-up after surgery was approximately 25 % while conservative treatment led to 
1.6 % increase in weight. In the same study, surgery was also considered to have more 
pronounced beneficial effect on co-morbid diseases (type 2 diabetes 
hypertriglyceridaemia, low HDL, blood pressure, hyperuricaemia) after both 2- and 10 
year follow-up compared to conservative treatment (24). In gastric bypass procedure the 
risk of mortality is 0.5-2.5 % and morbidity 10-20 % (27;28). 
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Gastric sleeve procedure  (Fig. 4) is quite new technique and was originally developed as 
the first part of a “two-stage” gastric bypass procedure among so-called super-obese (BMI 
≥ 60) patients (29).   
 
 
Fig. 4 Sleeve Gastrectomy. 
As a restrictive operation it has the advantage of not influencing in absorption (30). 
Gastric sleeve  also results in restriction of food intake but also changes in secretion of 
appetite-stimulating hormone called ghrelin due to resection of the upper part of stomach 
(fundus) from where ghrelin is normally secreted. Lately the SG has been used actively as 
such for the surgical treatment of obesity among patients with BMI between 35-60. The 
short-term results are promising and are equivalent in terms of weight loss and co-morbid 
diseases when compared to gastric bypass.  
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Data published to date show an average excess weight loss of 33-83 % after 1 year follow-
up. In spite of the wide range of data, results suggest that SG might be as effective as 
traditional weight loss surgeries that commonly have an average excess weight loss of 60-
85 % after 1 year of surgery (31). Sleeve Gastrectomy as a single operation for morbid 
obesity has gained attention, for it is “less complex” than some other alternative 
techniques like Roux-en-Y gastric bypass, having no gastrointestinal anastomosis (32). In 
addition no mesenteric defects are created eliminating the risk of internal hernia, no 
foreign material is used as in the case of gastric banding, the whole digestive tract remains 
accessible to endoscopy, it is not associated with dumping syndrome, the risk of peptic 
ulcer is low and the absorption of nutrients, vitamins, minerals and drugs is not altered 
(33). As a result, studies published on SG to date show fewer postoperative morbidities 
when compared to RYGB or BPD-DS (biliopancreatic diversion duodenal switch) (34). 
This makes SG an attractive choice for the treatment of high BMI patients in whom 
complications are more prevalent (35). In addition of its technical simplicity and lower 
risk ratios, the conversion of SG to RYGB or BPD-DS is relatively straight-forward. Thus 
after  12-18 months from SG, if the post-operative BMI still classifies patient as morbidly 
obese (BMI ≥ 40 kg/m2) SG can be converted into RYGB or BPD-DS (25). However 
long-term benefits are still unknown (36-37) and thus many questions remain about the 
current state and long-term outcome of SG.  
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 Recent studies suggest that both gastric sleeve and bypass surgery affect endocrine 
responses via changes in secretion of hormones. These hormones are secreted in periphery 
but have also central effects in regulation of feeding and energy balance. Numerous 
studies have proven the beneficial effects of bariatric surgery on the circulating levels of 
ghrelin and glucagon-like-peptide 1 (GLP-1) (38-39).  However it is likely that also other, 
yet unidentified factors play a role in the weight loss after SG.  
 
“Metabolic surgery” 
Over the past five years, the term “metabolic surgery” has become increasingly popular as 
a broader specialty encompassing bariatric surgery. In several studies Rubino et col. 
argues that the term better reflects the aims and mechanisms of surgery, and could 
improve access to surgery for those who need it most. However, despite the popularity of 
the nomenclature, a clear definition of metabolic surgery has not been established. 
Bariatric surgery, from the Greek “baros” meaning “weight”, is synonymous with weight 
loss surgery. Yet, the benefits and mechanisms of gastrointestinal procedures extend 
beyond weight loss, questioning the appropriateness of a name and practice entirely based 
on weight-reduction. In 2002, studies suggested that gastrointestinal surgery could be used 
with the primary intent to treat type 2 diabetes -  “diabetes surgery”.  
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The idea derived not only from the remarkable clinical effects of bariatric surgery on 
diabetes, but also from the recognition that the gastrointestinal tract is a major player in the 
regulation of glucose homeostasis. Ensuing investigations showing that the mechanisms of 
action of bariatric procedures are metabolic in nature, not just mechanic, provided 
scientific support for the surgical treatment of type 2 diabetes. The idea has progressively 
gained acceptance after a landmark “Diabetes Surgery Summit” in 2007, two world 
congresses dedicated to the subject and several position statements of relevant 
organizations, notably the International Diabetes Federation in 2011. “Metabolic” and 
“diabetes surgery”, however, are often incorrectly referred to as a surgical approach to 
treat diabetes in low BMI patients or as a set of novel and yet experimental operations. 
These are inaccurate definitions as they represent, at best, only two potential applications 
of metabolic surgery, not its defining characteristics. In fact, surgical disciplines are never 
defined by specific procedures, let alone by BMI ranges; rather, the definition and names 
of surgical subspecialties depend on the organ system whose anatomy is modified by the 
surgeon (as in neurosurgery, cardiac surgery, GI surgery) and/or by the diseases that one 
intends to treat (as in endocrine surgery). To help define the discipline of 
metabolic/diabetes surgery we investigated whether the name and, by inference, the 
primary intent of surgery can influence critical aspects of patient care, independent on the 
use of novel procedures or operating on non-obese patients. A “Metabolic Surgery 
Program” distinct from the “Bariatric Surgery Service” was recently established at a 
tertiary US academic medical center. The two programs differ for their stated goals but 
offer the same procedures and use identical eligibility criteria in patients with morbid 
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obesity. This unusual situation provided a unique opportunity to compare metabolic and 
bariatric surgery.These findings suggests that the name and, by inference, the intent of 
metabolic/diabetes surgery may influence patients' motives and perceptions of risks and 
benefits increasing the number of patients who seek surgery for medical reasons, rather 
than for physical problems or concerns related to body image. The substantial changes in 
demographic and clinical characteristics of surgical candidates have profound 
repercussions in terms of patients’ expectations, definition of success of treatment, pre-
operative evaluation and diagnostics, choice of procedure, postoperative care and follow-
up, multidisciplinary expertise and care team composition. These are defining aspects of 
clinical care that characterise metabolic/diabetes surgery as a new surgical subspecialty, 
distinct from traditional bariatric surgery. Based on the result of this study we propose that 
metabolic surgery be defined as “a set of gastrointestinal operations used with the intent to 
treat diabetes ("diabetes surgery") and metabolic dysfunctions (which include obesity)”. 
Given the important and distinct implications for patient care, using standard, Roux-en-Y 
gastric bypass to treat type 2 diabetes in patients with BMI above 35 should be considered 
“metabolic/diabetes surgery” not “bariatric surgery”. This means that, contrary to common 
misperceptions, the coming of age of metabolic surgery requires immediate attention to 
medical and public education more than major changes in health care policies. In fact, in 
patients with BMI above 35 surgical treatment of diabetes is now recommended by 
virtually all professional organizations and is already covered by most private and public 
health care providers. However, less than 2% of such patients in the USA, and far fewer in 
other countries, have access to surgery. Misconceptions of risks and benefits of surgical 
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treatment, possibly encouraged by the name and implicit aims of bariatric surgery, may act 
as a barrier for surgical access. Given the societal bias against obesity and the incorrect but 
common idea that one could lose weight by eating less and exercising more, weight 
reduction by surgery may look too risky or too costly for most physicians and payers. 
Using a name that better reflects aims and mechanisms of surgery may be the first step in 
the direction of improving access to surgery for those who need it. 
 
Evaluation of adipose tissue glucose metabolism in vivo 
The first two main techniques available to investigate directly adipose tissue 
metabolism in vivo were the arteriovenous technique (Frayn et al., 1989) and 
microdialysis (Arner & Bulow, 1993; Arner & Bolinder, 1991). The evolution of the 
technology permitted the combination of the above-mentioned techniques with 
radioactive and isotopic tracers, usually used for systemic measurements (Coppack et 
al., 1994). 
 
- Microdialysis 
This technique allow a direct measurement of interstitial concentrations of various 
substances (glucose, lactate, glycerol, insulin) that can diffuse through a 
semipermeable membrane (Lonnroth et al. 1987; Ungerstedt & Hallstrom 1987). 
FFAs cannot be studied with this technique due to their lipophilic properties. The 
technique is based on the mimic the passive function of a capillary by perfusing a thin 
microdialysis catheter located in the tissue.  
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A probe with a semipermeable membrane is placed into tissue of interest (e.g. 
adipose tissue) and perfused with neutral fluid which equilibrates with the 
extracellular fluid by passive diffusion. Calibrated assessment of interstitial fluid 
(dyalisate) is needed for the measurement of substrate concentration, and this 
recovery of the substance refers to the relationship between dialysate and interstitial 
concentration of the analyte. Thereafter metabolic uptake can be calculated based on 
Fick’s equation (reviewed in Arner & Bulow 1993) (Peltoniemi et al. 2000; 
Stallknecht et al. 2000).This requires knowledge of regional blood flow and 
permeability surface area product (PS). 
This technique gives the opportunity to study local tissue metabolism and to perform  
local manipulation with metabolically active pharmacological agents (Arner 1995). 3-
O-methyl glucose can be used to determine glucose transport in isolatedfat cells and 
further can be studied the conversion of glucose to lipids (14C-labelled 
glucose),lactate and carbon dioxide by combining the tracer with microdialysis or 
arteriovenous methods (Arner 1995). Extracellular glucose concentration is close to 
arterial concentration (Simonsen et al. 1992), thus, interpretations concerning glucose 
uptake by the tissue involved can be drawn by monitoring extracellular and arterial 
glucose concentration simultaneously. When microdialysis is combined with an 
injection of radiolabelled deoxyglucose,measuring the radioactivity can be used as a 
means of monitoring the proportion of extracellular deoxyglucose, provided that a 
sensitive detection method is used.  
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The limits of this technique are that is restricted on studies with small and water-
soluble metabolities and that it can only study subcutaneous adipose tissue regions. 
 
- Arterio-venous technique 
The arterio-venous technique (A-V) was presented in 1989 (Frayn et al.). Through 
this technique it is possible to determined arterio-venous (A-V) or venous-arterial (V-
A) differences in substrate concentration by introducing one catheter in any artery 
and another catheter to a vein draining subcutaneous adipose tissue in the anterior 
abdominal wall. Thus the arterio-venous (A-V) differences  denotes substances taken 
up by the tissue and the venous-arterial (V-A) differences denotes substances released 
over the cannulated adipose tissue region (Frayn et al. 1989). If quantification of 
substrate uptake and release is preferred, blood flow measurement is further needed.  
As in using microdialysis, studies have some limitations; they are restricted on 
abdominal subcutaneous adipose tissue depots and vein cannulation is time-
consuming and rather difficult. However, the method gives accurate information 
about subcutaneous adipose tissue metabolism. 
The arteriovenous technique has some advantages compared to microdialysis. It can 
be used to estimate absolute substrate flux of hydrophobic molecules and lipoprotein 
particles, while this is not possible with microdialysis. On the other hand, both 
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techniques require blood flow for the estimates, and microdialysis allows 
simultaneous blood flow assessment and is easier to perform than arteriovenous 
techniques, plus it can study more than one adipose depot. A limitation for both 
techniques is the inability to study the intra-abdominal adipose tissue (Frayn et al., 
1997), and a negative aspect can be their invasiveness. 
Measurement of splanchnic FFA release by arteriovenous technique (hepatic vein 
catheterization) and isotope dilution gives only indirect estimates of visceral adipose 
tissue lipolysis (Nielsen et al., 2004), since it is impractical to obtain direct 
measurements from the portal vein in humans. This limitation can be overcome by 
the use of non-invasive PET imaging of the abdominal area, by means of which the 
rate of lipolysis can be estimated in relation to the specific fat depot mass. 
Dietary FA uptake in subcutaneous and visceral adipose tissue in normal weight 
humans has been compared by tissue biopsies, showing that VAT accumulates more 
dietary fat (milligram meal fat per gram of adipose tissue lipid) than either upper 
body subcutaneous or lower body subcutaneous fat (Jensen, 2008). Similar results, 
but related to circulating FFA, have been described in lean subjects with the use of 
PET and a long chain FA tracer (18F-FTHA) (Hannukainen et al., 2010), but before 
the present study there were no similar investigations in obese subjects. 
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- The euglicemic clamp technique have been widely used in humans for 
determining whole-body insulin sensitivity; afterwards, the abdominal arterio-
venous (A-V) technique (Frayn et al.). and microdialysis (Lonnroth et al. 1987) 
have  also enabled  to study directly the adipose tissue metabolism in vivo in 
humans. This is the gold standard method for determination of whole insulin 
sensitivity. The method requires a control of continuos glucose monitoring and 
adjusting of glucose infusion according plasma concentration. The limitations 
are that this method is difficult to apply in daily clinical practice and is 
preferentially used in clinical studies. The plasma glucose concentration is 
acutely raised to 125 mg/dl above basal levels by a priming infusion of 
glucose. The desired hyperglycemic plateau is subsequently maintained by 
adjustment of a variable glucose infusion, based on the negative feedback 
principle. Because the plasma glucose concentration is held constant, the 
glucose infusion rate is an index of glucose metabolism. Under these 
conditions of constant hyperglycemia, the plasma insulin response is biphasic 
with an early burst of insulin release during the first 6 min followed by a 
gradually progressive increase in plasma insulin concentration. Euglycemic 
insulin clamp technique. The plasma insulin concentration is acutely raised and 
maintained at approximately 100 muU/ml by a prime-continuous infusion of 
insulin. The plasma glucose concentration is held constant at basal levels by a 
variable glucose infusion using the negative feedback principle. Under these 
steady-state conditions of euglycemia, the glucose infusion rate equals glucose 
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uptake by all the tissues in the body and is therefore a measure of tissue 
sensitivity to exogenous insulin. 
 
- Positron emission tomography (PET) 
Positron emission tomography (PET)  is a nuclear medicine technique used in 
many medical areas (oncology, neuroscience, cardiology, orthopedics) in both 
clinical and research purposes for the production of  bio-imaging and is considered 
the gold standard method to study metabolic pathways in vivo in human tissue.  In 
PET imaging, natural biological molecules can be labelled with a positron-emitting 
isotope that is capable of producing two γ-rays through emission of a positron from 
its nucleus, which eventually annihilates with a nearby electron to produce two 511 
KeV γ-rays at ~180° apart. The coincidence detection of both  γ--rays within 
nanoseconds of each other defines the line of response in space and thus the direction 
of flight. Coincidence detection is obtained throw a number of parallel rings of small 
detector elements in a cylindrical geometry, simultaneously providing back-to-back 
emission of the radioactivity distribution from many different directions. 
The coincidence events measured at all angular positions are used to reconstruct an 
image that represents the localization and concentration of the positron-emitting 
radioisotope within the organ that was scanned. A complex computerized algorithm 
running on a workstation is responsible of the reconstruction of the back-to-back 
projections in either two or three dimensions depending on the design of the 
detectors. 
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In general, radiopharmaceuticals developed for PET have high specificity and 
sensitivity for a given physiological process, requiring minimal amounts of labeled 
material (0.1-10 nmoles per dose). The fact that only small amounts of radiolabeled 
molecules are needed offers the advantage that biological processes are not disturbed. 
The PET-radiopharmaceuticals tracers (Fig. 5) are commonly produced using 
isotopes of elements often occurring in natural biological compounds (nitrogen, 
oxygen, carbon), so a variety of compounds are available and suitable for labeling in 
order to become radiotracers. In fact, labeled radio-water or ammonia (H215O, 13NH3), 
glucose and fatty acids (e.g. 11C-glucose, 11C-methylglucose, 11C-palmitate or 11C-
oleate) or their analogues, i.e. 18F-2-fluoro-2deoxyglucose and 18F-
fluoroheptadecanoic acid (18F-FDG and 18F-FTHA) have been used to quantify organ 
perfusion (participating in the delivery of substrates through the circulation), and the 
uptake and intracellular fate of substrates (e.g. glucose transport-phosphorylation, 
fatty acid oxidation and storage), respectively. 
 
34 
 
 
 
35 
 
Fig. 5 PET principles and the most commonly used PET tracers with the 
corresponding target myocardial metabolic processes are shown in the bottom table. 
(Figure from Iozzo, 2010). 
 
Glucose uptake 
[18F]FDG is a labelled positron-emitting glucose analogue in which the hydrogen in 
the 2-positron is replaced by [18F]. Glucose and [18F]FDG are structurally more 
similar than glucose and either hydrogen or carboxyl labelled deoxyglucoses. The 
high specific radioactivity of [18F]FDG ensures that small molar amounts can be 
used and glucose metabolism is not disturbed. Further, isotope discrimination is 
regarded minor. Intracellularly, [18F]FDG is phosphorylated by herokinase but is 
only slowly and minimally metabolized thereafter. [18F]FDG lacks the 2-hydroxyl 
group and therefore cannot be further metabolized via the glycolytic pathway and is 
trapped in the tissue (Phelps et al. 1979).  
 
 
 
 
 
 
 
 
36 
 
AIMS OF THE STUDY 
 
To investigate the effect of bariatric surgery on glycemic control, hormones and on 
biochemical markers. 
To evaluate the possible differences between the two surgical procedures (sleeve 
gastrectomy vs. gastric bypass). 
To assess the change in adipose tissue and skeletal muscle glucose uptake in 
morbidly obese  patients prior to, and after bariatric procedures. 
 
MATERIALS AND METHODS 
PARTECIPANTS 
 
 
A total  of  23 morbidly obese patients (male/female 4/19,  age 46.5±9, BMI 43.3±3.8 
kg/m2) undergoing bariatric surgery were recruited at the Department of Surgery, 
Turku University Hospital, Finland, comparing sleeve gastrectomy (SG) and Roux-en 
Y gastric bypass (RYGB) All patients were studied with PET using [18F]FDG before 
and six months after bariatric surgery. 
Inclusion and exclusion criteria followed international guidelines (40) and restrictions 
in imaging devices.  Fourteen patients were non-diabetic, including five subjects with 
impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT). Nine 
patients had type 2 diabetes mellitus according to the criteria of the American 
Diabetes Association (41).  
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At the screening, four patients were newly diagnosed with type 2 diabetes, based on 
the results of the oral glucose test (OGTT) and were treated with metformin. The 
other five patients, in which the median diabetes duration was 2.8 years, were treated 
by oral hypoglycaemic agents (2 metformin; 1 
metformin/sulphonylurea/gliptin;1metformin/pioglitazone/gliptin and 1 metformin/ 
pioglitazone). Thirteen (7 diabetic and 6 non-diabetic) patients underwent Roux-en Y 
gastric bypass (RYGB) and 10 (2 diabetic and 8 non-diabetic) patients sleeve 
gastrectomy (SG). Ten healthy non-obese age-matched controls  (male/female 
2/8,age 47.3±6, BMI  23.6±1.8  kg/m2) with normal OGTT results were recruited 
using advertisement in a local newspaper. The nature, purpose and potential risks of 
the study were explained to all subjects before they gave their written informed 
consent to participate. The study was approved by the local ethics committee and 
performed in compliance with the Declaration of Helsinki. 
The total dose accounting all PET-studies is less than 15.8 mSv. For the control 
group, the total dose was about 6.8 mSv. 
Surgical inclusion criteria for the patient population 
1. BMI > 40 kg/m2 or ≥ 35 if there is an additional risk factor (lean control 
group BMI 18-27 kg/m2) 
2. Age: 18-60 years 
3. Previous, carefully planned, conservative treatments for obesity have failed 
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Surgical contraindications for the patient population 
1. BMI over 60 
2. Mental disorder or poor compliance 
3. Eating disorder or excessive use of alcohol 
4. Active ulcus-disease 
 
PET exclusion criteria 
1. Diabetes requiring insulin treatment or fasting glucose more than 7 mmol/l 
2. Weight more than 170 kg before surgery 
 
MRI exclusion criteria  
1. Pacemaker 
2. Inner ear implants 
3. Pregnancy 
4. Metal objects in body including metallic prostheses, artificial valve 
prostheses, surgical clipses, braces, foreign fragments or tattoo 
5. Weight more than 200 kg (weight limit of the MRI table) 
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STUDY DESIGN 
 
The study was prospective randomized controlled clinical study.  The centres involved 
were Turku University Hospital and Turku PET Centre. All subjects underwent a 
screening visit before inclusion in the study. At the visit, an OGTT was performed. During 
the OGTT, blood samples were taken before and at 30,60,90, and 120 min, for glucose, 
insulin and C-peptide.  
At baseline, magnetic resonance imaging  (MRI) and positron emission tomography (PET) 
studies were performed: first in fasting state and then during euglycemic hyperinsulinemic 
clamp. The order of the days was randomised. These measurements were repeated six 
months, post-operatively. The baseline studies were carried out before the patient started a 
four–week very-low-calorie-diet (VLCD) prior the surgery.  
Subjects were instructed to fast for 7-8 hours prior to the MRI examination. A whole-body 
magnetic resonance imaging (MRI) was performed to obtain an anatomical reference for 
PET. Data from MRI studies were obtained using either 1.5 Tesla – or 3.0 Tesla system 
(Intera, Philips Medical Systems, Best, the, Netherlands).    
PET studies after overnight fasting. Anti-diabetic treatment was withheld 24-72 h before 
the metabolic studies. The results from MRI and PET were compared to results from MRI 
and PET studies performed in the healthy non-obese age-matched controls.                                                          
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Design for the PET study day :  Each study consisted of a 100 ±10 min euglycemic 
hyperinsulinemic period. At 5 minutes after the start of the glucose-insulin clamp, 
[18F]FDG PET was injected intravenously and the abdomen area was scanned for 55 min 
and then the femoral region for 15 min. 
Adipose tissue and femoral studies 
 
Additionally T1WFFE imageswere obtained at the level of the thigh for the anatomical 
reference for PET. 
 
Methods 
Roux-en Y gastric bypass (RYGB) and sleeve gastrectomy (SG) were performed as 
previously described. Biochemical and immunological analyses were obtained. 
The PET studies were performed both in fasting state and during an euglycemic 
hyperinsulinemic clamp, on separate days less than two weeks apart.  
For PET studies, two venous catheters were inserted, one for infusion of glucose, 
insulin, and for injection of [18F]FDG, and another for arterialised blood sampling. 
The euglicemic hyperinsulinemic clamp technique was used for quantifying insulin 
secretion and resistance, as previously described (42).  
The rate of insulin infusion was 1 mU/Kg/min (Actrapid; Novo Nordisk, Copenhagen, 
Denmark). During hyperinsulinemia, euglycemia was maintained by a variable infusion 
rate of 20% glucose based on plasma glucose determinations taken every 5-10 min from 
arterialized blood.  
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Blood samples were obtained at time intervals in the fasting state and during the clamp, for 
the  measurement of plasma glucose and insulin levels. Each study consisted of a 111-min 
euglycemic hyperinsulinemic (1 mU/kg ˙min ֿ◌)period. Fifty-five minutes after the start of 
the clamp, [18F]FDG was injected and scanning started from the brain, followed by liver, 
abdomen and legs.  
[18F]FDG, that was synthesized in the Radiopharmaceutical Chemistry Laboratory at 
Turku PET Centre with an automatic apparatus (Hamacher), was injected intravenously 
over 15 s. Patient was positioned into the camera. Attenuation correction is performed. ~6 
mCi (220 MBq) of [18F]FDG is injected intravenously over 2 min. The PET-scanning 
started from the brain, followed by liver, abdomen and legs.  All scans were dynamic.  
 
 
 
PET images were acquired using the PET scanner GE Advance (General Electric 
Medical Systems, Milwaukee, WI, USA) with the resolution of 3.8 mm.  
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All data image were corrected for dead-time, decay and photon attenuation. Plasma 
radioactivity was measured with an automatic gamma counter (Wizard 1480 3", 
Wallac, Turku, Finland). Heart rate and blood pressure were monitored during the 
studies to calculate the rate-pressure product. Plasma glucose was frequently 
measured during the PET study.  
Carimas software (Turku PET Centre, Turku, Finland) was used to manually drawn 
regions of interest (ROIs) over the adipose tissue region. 
PET images were coregistered with MRI images for anatomical reference to localise 
the area of interest.  
The regions of interest (ROIs) were drawn manually (Fig. 6) into MRI images 
coregistered to PET images in the subcutaneous antero-lateral and antero-medial 
adipose tissue compartments in the femoral region in four cross-sectional slices (x 
ROI per analysis per patient), carefully avoiding large blood vessels (Raitaki et 
all.1996).  
 
Fig. 6  PET image of the femoral region of interest (ROI during euglycemi- 
hyperinsulinemic conditions. 
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Time-activity curves (TACs) and input curves extracted from PET images were used 
to obtain the fractional uptake rate (FUR) via a graphical method (ref), that is similar 
to the well known Gjedde-Patlak method (ref)using an approximation of Gjedde-
Patlak (fractional uptake rate, i.e. FUR).  
 
 
Fractional uptake rate (FUR) 
 
FUR is a simple PET quantifier, calculated as a ratio of tissue activity at time T and 
integral of plasma activity from time 0 to T (Camici et al., 1986; Allman et al., 1993; 
Ishizu et al. 1994 and 1995; Rutland et al., 2000) (Fig. 7). 
FUR=Ctissue(T)∫T0Cplasma(t)dtThus the unit of FUR is min-1 (Thie 1995). FUR can 
be calculated from a single late PET scan, like SUV, but blood sampling from the 
injection to the scan time is required.  FUR is an approximation to the Patlak plot 
(MTGA for irreversible uptake) slope Ki, to the extent that at large T (late time after 
injection) the effective distribution volume term in Patlak analysis is not important (y 
axis intercept is assumed to be 0). FUR and SUV are proportional, related by plasma 
clearance rate and a dimensionless initial distribution volume (Thie 1995). 
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Fig. 7 For calculation of FUR, plasma TAC is integrated from 0 (injection time) to 
the middle time of PET frame (or middle point of PET time range when PET scan 
consists of several frames). Note that integration to the end of PET data would be a 
mistake. Mean tissue concentration is then divided by plasma integral to get the FUR 
value. 
Metabolic rate 
 
When the PET tracer is an analog of glucose (e.g. [F-18]FDG) and it is metabolically 
trapped in tissue during the PET scan, the FUR estimate, like influx rate (Ki) from 
Patlak plot, can be used to calculate the metabolic rate of the native substrate. For 
example, in [F-18]FDG the FUR can be multiplied by concentration of glucose in 
plasma, and divided by the appropriate lumped constant, to get an estimate of glucose 
uptake rate.  
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Naturally, the FUR-based metabolic rates contain the same bias as FUR itself when 
compared to metabolic rates based on Ki. The rate of adipose tissue glucose uptake 
was obtained by multiplying Ki by the plasma glucose concentration and a lumped 
constant of 1.4. 
Lumped constant (LC) 
The lumped constant for formulated by Sokoloff et al. (1977), based on the 
biochemical principles of competitive substrate kinetics. It accounts for the 
differences in transport and phosphorylation rates between D-glucose and 2-fluoro-2-
deoxy-D-glucose, and is used to transform the [18F]FDG uptake rate to glucose 
uptake rate. The concept of lumped constant can be used with any metabolism PET 
tracer which competes with a natural substrate.  
LC of [18F]FDG 
Brain 
A common assumption in FDG PET studies is that lumped constant is uniform over 
the whole brain and in all subject and patient groups, but this is not strictly true: 
Hexokinase favours glucose over FDG, and transport favours FDG over glucose. 
Although there are several different estimates on the normal value of LC in the brain, 
the estimates are always less than 1.0, representing that in normal condition the 
phosphorylation is the rate-limiting step in glucose uptake. 
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In supply limited conditions (hypoglycemia and ischemia) LC increases as shown by 
Crane et al. (1981) and Hawkins et al. (1981). Lumped constant is a function of the 
rate constants (Sokoloff et al. 1977). The variability of LC results primarily from 
changes in k3/k2 for glucose and for FDG (k3*/k2*) as is expressed in below (Phelps et 
al. 1983): 
LC∝1+(p/q)×k∗3k∗21+k∗3k∗2(1) 
Phelps et al. (1983) used values p=0.50 and q=1.67 (q/p=3.34) to estimate the 
changes in LC between normal and ischemic brain regions. This equation was used 
by Sasaki et al. (1986) to estimate whether LC is uniform over the whole brain. 
Kuwabara and Gjedde (1990; 1991) derived equation for LC which is independent of 
the model used: 
LC=φ+(τ−φ)×K∗iK∗1(2), where Ki* is the unidirectional clearance from the 
circulation to the metabolic compartment (net influx rate), τ is the ratio between FDG 
and glucose clearances (K1*/K1), and φ is the phosphorylation ratio between FDG and 
glucose (k3*/k3). Kuwabara and Gjedde (1991) used estimates τ=1.10 and φ=0.30. 
Before that, Crane et al. (1983) have used estimates τ=1.67 and φ=0.55 in rat studies. 
LC in human adipose tissue is 1.14 (Virtanen et al., 2001). 
 
 
 
ASSESSMENTS 
 
 
Pre-operative studies 
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The history of carefully planned, conservative treatments for obesity was assessed when 
patients seeking surgical treatment came in policlinic. A possible endocrinolocigal disease 
was excluded by the endocrinologist. Eating disorder was excluded by dietician using 
eating questionnaires BES and BITE (Fig. 8).  In addition to EKG the following laboratory 
values are measured pre-operatively : CBC (complete blood count), TSH, urate, fasting 
plasma glucose, GHbA1c, INR (blood coagulation), albumin, ALAT, AFOS, GT, total 
cholesterol, HDL, LDL,  TG, creatine, Na, K, Ca, Pi, B12, D25, folate, hs-CRP, plasma 
cytokines, IL1β, adiponectin, leptin, bile acids, gastrointestinal peptides (CCK, bombesin, 
gastrin-releasing peptide, GIP, GLP1, peripheral PYY, pancreatic polypeptide, 
oxyntomodulin, ghrelin, obestatin), lipoprotein fractions, serum fatty acid composition, 
non-cholesterol sterols (squalene, cholestenol, desmosterol, lathosterol, campesterol, 
sitosterol, cholestanol, avenasterol) and the sizes of LDL - & HDL-particles. 
 In addition oral glucose tolerance test (OGTT) of 75 g with insulin, fatty acid and c-
peptide measurements (time points 0 and 120 minutes) and dexamethasone test of 1 mg, 
were done.  Pre-operative gastroscopy was performed to all patients in the policlinic of 
surgery. During gastrointestinal endoscopy routine biopsies were taken from duodenum, 
antrum and corpus. This visit included the decision if the patient was eligible for surgery. 
If the patient is accepted, the surgical risk factors and the study information were carefully 
explained.  
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Randomisation either in the gastric sleeve or gastric bypass group was done using closed 
envelopes.  Pre-operative quality of life was assessed using BAROS-survey (Fig.9). After 
this, selected patients were visited the dietetian. Dietitian gaves first instructions about the 
pre-operative very-low-calorie-diet (VLCD) phase and second nutritional advice about the 
post-operative phase. During the VLCD-phase patients usually lost weight approximately 
about 1.5-2.5 kg in a week. Before the surgery an abdominal ultrasound was performed to 
exclude gallstones. If gallstones were found, they were removed during the bariatric 
surgery.  
Fig. 8 Questionnaires BES and BITE 
TERVEYTEEN LIITTYVÄN ELÄMÄNLAADUN KYSELYLOMAKE (15D©): 
SEURANTA 
 
 
Ohje:  Lukekaa ensin läpi huolellisesti kunkin kysymyksen kaikki vastausvaihtoehdot. 
Merkitkää sitten rasti (x) sen vaihtoehdon kohdalle, joka parhaiten kuvaa nykyistä 
terveydentilaanne. Menetelkää näin kaikkien kysymysten 1-16 kohdalla. Kustakin 
kysymyksestä rastitetaan siis yksi vaihtoehto. 
 
 
 
KYSYMYS 1.  Liikuntakyky 
 
1 (  )   Pystyn kävelemään normaalisti (vaikeuksitta) sisällä, ulkona ja portaissa. 
2 (  )   Pystyn kävelemään vaikeuksitta sisällä, mutta ulkona ja/tai portaissa on pieniä vaikeuksia. 
3 (  )   Pystyn kävelemään ilman apua sisällä (apuvälinein tai ilman), mutta ulkona ja/tai portaissa melkoisin 
 vaikeuksin tai toisen avustamana. 
4 (  )   Pystyn kävelemään sisälläkin vain toisen avustamana. 
5 (  )   Olen täysin liikuntakyvytön ja vuoteenoma. 
 
 
KYSYMYS 2.  Näkö 
 
1 (  )   Näen normaalisti eli näen lukea lehteä ja TV:n tekstejä vaikeuksitta (silmälaseilla tai ilman). 
2 (  ) Näen lukea lehteä ja/tai TV:n tekstejä pienin vaikeuksin (silmälaseilla tai ilman). 
3 (  )   Näen lukea lehteä ja/tai TV:n tekstejä huomattavin vaikeuksin (silmälaseilla tai ilman). 
4 (  )   En näe lukea lehteä enkä TV:n tekstejä ilman silmälaseja tai niiden kanssa, mutta näen kulkea  
 ilman opasta. 
5 (  )   En näe kulkea oppaatta eli olen lähes tai täysin sokea. 
 
 
KYSYMYS 3.  Kuulo 
 
1 (  )   Kuulen normaalisti eli kuulen hyvin normaalia puheääntä (kuulokojeella tai ilman). 
2 (  )   Kuulen normaalia puheääntä pienin vaikeuksin. 
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3 (  )   Minun on melko vaikea kuulla normaalia puheääntä, keskustelussa on käytettävä normaalia 
kovempaa  puheääntä. 
4 (  )   Kuulen kovaakin puheääntä heikosti; olen melkein kuuro. 
5 (  )   Olen täysin kuuro. 
 
 
KYSYMYS 4.  Hengitys 
 
1 (  )   Pystyn hengittämään normaalisti eli minulla ei ole hengenahdistusta eikä muita hengitysvaikeuksia. 
2 (  )   Minulla on hengenahdistusta raskaassa työssä tai urheillessa, reippaassa kävelyssä tasamaalla  
 tai lievässä ylämäessä. 
3 (  )   Minulla on hengenahdistusta, kun kävelen tasamaalla samaa vauhtia kuin muut ikäiseni. 
4 (  )   Minulla on hengenahdistusta pienenkin rasituksen jälkeen, esim. peseytyessä tai pukeutuessa. 
5 (  )   Minulla on hengenahdistusta lähes koko ajan, myös levossa. 
 
 
KYSYMYS 5.  Nukkuminen 
 
1 (  )   Nukun normaalisti eli minulla ei ole mitään ongelmia unen suhteen. 
2 (  )   Minulla on lieviä uniongelmia, esim. nukahtamisvaikeuksia tai satunnaista yöheräilyä. 
3 (  )   Minulla on melkoisia uniongelmia, esim. nukun levottomasti tai uni ei tunnu riittävältä. 
4 (  )   Minulla on suuria uniongelmia, esim. joudun käyttämään usein tai säännöllisesti unilääkettä, herään 
 säännöllisesti yöllä ja/tai aamuisin liian varhain. 
5 (  )   Kärsin vaikeasta unettomuudesta, esim. unilääkkeiden runsaasta käytöstä huolimatta nukkuminen 
on  lähes mahdotonta, valvon suurimman osan yöstä. 
 
 
KYSYMYS 6.  Syöminen 
 
1 (  )   Pystyn syömään normaalisti eli itse ilman mitään vaikeuksia. 
2 (  )   Pystyn syömään itse pienin vaikeuksin (esim. hitaasti, kömpelösti, vavisten tai erityisapuneuvoin). 
3 (  )   Tarvitsen  hieman toisen apua syömisessä. 
4 (  )   En pysty syömään itse lainkaan, vaan minua pitää syöttää. 
5 (  )   En pysty syömään itse lainkaan, vaan minulle pitää antaa ravintoa letkun avulla tai suonensisäisesti. 
 
 
KYSYMYS 7.  Puhuminen 
 
1 (  )   Pystyn puhumaan normaalisti eli selvästi, kuuluvasti ja sujuvasti. 
2 (  )   Puhuminen tuottaa minulle pieniä vaikeuksia, esim. sanoja on etsittävä tai ääni ei ole riittävän 
 kuuluva tai se vaihtaa korkeutta. 
3 (  )   Pystyn puhumaan ymmärrettävästi, mutta katkonaisesti, ääni vavisten, sammaltaen tai änkyttäen. 
4 (  )   Muilla on vaikeuksia ymmärtää puhettani. 
5 (  )   Pystyn ilmaisemaan itseäni vain elein. 
 
 
KYSYMYS 8.  Eritystoiminta 
 
1 (  )   Virtsarakkoni ja suolistoni toimivat normaalisti ja ongelmitta. 
2 (  )   Virtsarakkoni ja/tai suolistoni toiminnassa on lieviä ongelmia, esim. minulla on virtsaamisvaikeuksia 
tai  kova tai löysä vatsa 
3 (  )   Virtsarakkoni ja/tai suolistoni toiminnassa on melkoisia ongelmia, esim. minulla on satunnaisia 
 virtsanpidätysvaikeuksia tai vaikea ummetus tai ripuli. 
4 (  )   Virtsarakkoni ja/tai suolistoni toiminnassa on suuria ongelmia, esim. minulla on säännöllisesti   
 "vahinkoja" tai peräruiskeiden tai katetroinnin tarvetta. 
5 (  )  En hallitse lainkaan virtsaamista ja/tai ulostamista. 
 
 
KYSYMYS 9.  Tavanomaiset toiminnot 
 
1 (  )   Pystyn suoriutumaan normaalisti tavanomaisista toiminnoista (esim. ansiotyö, opiskelu, kotityö,  
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 vapaa-ajan toiminnot). 
2 (  )   Pystyn suoriutumaan tavanomaisista toiminnoista hieman alentuneella teholla tai pienin vaikeuksin. 
3 (  )   Pystyn suoriutumaan tavanomaisista toiminnoista huomattavasti alentuneella teholla tai  
 huomattavin vaikeuksin tai vain osaksi. 
4 (  )   Pystyn suoriutumaan tavanomaisista toiminnoista vain pieneltä osin. 
5 (  )   En pysty suoriutumaan lainkaan tavanomaisista toiminnoista. 
 
 
10.  Henkinen toiminta 
 
1 (  )   Pystyn ajattelemaan selkeästi ja johdonmukaisesti ja muistini toimii täysin moitteettomasti. 
2 (  )   Minulla on lieviä vaikeuksia ajatella selkeästi ja johdonmukaisesti, tai muistini ei toimi täysin  
 moitteettomasti 
3 (  )   Minulla on melkoisia vaikeuksia ajatella selkeästi ja johdonmukaisesti, tai minulla on jonkin verran 
 muistinmenetystä 
4 (  )   Minulla on suuria vaikeuksia ajatella selkeästi ja johdonmukaisesti, tai minulla on huomattavaa  
 muistinmenetystä 
5 (  )   Olen koko ajan sekaisin ja vailla ajan tai paikan tajua 
 
 
 
KYSYMYS 11.  Vaivat ja oireet 
 
1 (  )   Minulla ei ole mitään vaivoja tai oireita, esim. kipua, särkyä, pahoinvointia, kutinaa jne. 
2 (  )   Minulla on lieviä vaivoja tai oireita, esim. lievää kipua, särkyä, pahoinvointia, kutinaa jne. 
3 (  )   Minulla on melkoisia vaivoja tai oireita, esim. melkoista kipua, särkyä, pahoinvointia, kutinaa jne. 
4 (  )   Minulla on voimakkaita vaivoja tai oireita, esim. voimakasta kipua, särkyä, pahoinvointia, kutinaa jne. 
5 (  )   Minulla on sietämättömiä vaivoja ja oireita, esim. sietämätöntä kipua, särkyä, pahoinvointia, kutinaa 
 jne. 
 
 
KYSYMYS 12.  Masentuneisuus 
 
1 (  )   En tunne itseäni lainkaan surulliseksi, alakuloiseksi tai masentuneeksi. 
2 (  )   Tunnen itseni hieman surulliseksi, alakuloiseksi tai masentuneeksi. 
3 (  )   Tunnen itseni melko surulliseksi, alakuloiseksi tai masentuneeksi. 
4 (  )   Tunnen itseni erittäin surulliseksi, alakuloiseksi tai masentuneeksi. 
5 (  )   Tunnen itseni äärimmäisen surulliseksi, alakuloiseksi tai masentuneeksi. 
 
 
 
KYSYMYS 13.  Ahdistuneisuus 
 
1 (  )   En  tunne itseäni lainkaan ahdistuneeksi, jännittyneeksi tai hermostuneeksi. 
2 (  )   Tunnen itseni hieman ahdistuneeksi, jännittyneeksi tai hermostuneeksi. 
3 (  )   Tunnen itseni melko ahdistuneeksi, jännittyneeksi tai hermostuneeksi. 
4 (  )   Tunnen itseni erittäin ahdistuneeksi, jännittyneeksi tai hermostuneeksi. 
5 (  )   Tunnen itseni äärimmäisen ahdistuneeksi, jännittyneeksi tai hermostuneeksi. 
 
 
 
KYSYMYS 14.  Energisyys 
 
1 (  )   Tunnen itseni terveeksi ja elinvoimaiseksi. 
2 (  )   Tunnen itseni hieman uupuneeksi, väsyneeksi tai voimattomaksi. 
3 (  )   Tunnen itseni melko uupuneeksi, väsyneeksi tai voimattomaksi. 
4 (  )   Tunnen itseni erittäin uupuneeksi, väsyneeksi tai voimattomaksi, lähes "loppuun palaneeksi". 
5 (  )   Tunnen itseni äärimmäisen uupuneeksi, väsyneeksi tai voimattomaksi, täysin "loppuun palaneeksi". 
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KYSYMYS 15.  Sukupuolielämä 
 
1 (  )   Terveydentilani ei vaikeuta mitenkään sukupuolielämääni. 
2 (  )   Terveydentilani vaikeuttaa hieman sukupuolielämääni. 
3 (  )   Terveydentilani vaikeuttaa huomattavasti sukupuolielämääni. 
4 (  )   Terveydentilani tekee sukupuolielämäni lähes mahdottomaksi. 
5 (  )   Terveydentilani tekee sukupuolielämäni mahdottomaksi. 
 
 
KYSYMYS 16.  Terveydentila kaiken kaikkiaan 
 
Verrattuna tilanteeseen (edellisen kyselyn aikaan) ennen hoitoa, terveydentilani on nyt kaiken kaikkiaan  
1 (  )   paljon parempi 
2 (  )   hieman parempi 
3 (  )   samanlainen 
4 (  )   hieman huonompi 
5 (  )    paljon huonompi 
 
Fig. 9 BAROS-survey 
FRÅGEFORMULÄR BETRÄFFANDE LIVSKVALITETEN HOS 
PATIENTER, VILKA KOMMER FÖR OPERATIV BEHANDLING AV 
SJUKLIG ÖVERVIKT 
 
 
 
Mår Ni rent allmänt 
  Mycket dåligt      Dåligt      Ganska bra     Bra     Mycket bra 
 
Hur klarar Ni er socialt  
  Mycket dåligt      Dåligt   Ganska bra     Bra     Mycket bra 
 
Kan Ni delta i olika motionsaktiviteter 
  Mycket dåligt     Dåligt      Ganska Bra     Bra    Mycket bra 
 
Hurudan är Er arbetsförmåga 
  Mycket dålig      Dålig     Ganska bra     Bra     Mycket bra 
 
Hur är det med Ert intresse för sex 
  Mycket dåligt      Dåligt      Ganska bra     Bra     Mycket bra 
 
Lider Ni av någon av följande sjukdomart: 
  Förhöjt blodtryck 
  Astma 
  Diabetes 
  Depression 
  Belastningsrelaterade ledsmärtor 
52 
 
  Sömnapnea 
  Någon annan sjukdom, vilken?___________________________________ 
 
Medicinering, vilken?______________________________________________ 
___________________________________________________________ 
 
Post-operative control studies 
 
Post-operative controls were done according to clinical treatment protocol. Per oral 
nutrition was started on the first day after surgery (1st post-operative day). PPI (proton 
pump inhibitor) –medication was started post-operatively and was continued 3 months. 
Patients remained in hospital 2-5 days after surgery. After leaving the hospital patients 
received a weight-loss-form in where weight was self-recorded weekly.  During post-
operative control visits , laboratory tests were taken according to normal treatment 
procedure and BAROS-survey, measuring quality of life, was filled. Depending on the rate 
of weight loss during control visits of 1-2 year, patients were referred to cosmetic surgery 
evaluation. The need of possible cosmetic surgery was evaluated according to normal 
treatment procedure.  
Indirect calorimetry 
Calorimetry is the measurement of energy expenditure (EE). Direct calorimetry 
measures total heat loss from the body; indirect calorimetry measures total energy 
produced by the body. With the former, the subject is placed in a thermally isolated 
chamber, and the heat that he/she dissipates (by evaporation, radiation, and 
conduction/conversion) is accurately collected and precisely measured. 
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The use of such a chamber for direct calorimetry is an arduous and slow process. 
Indirect calorimetry, calculating metabolic rate from measurements of VO2 and 
VCO2 is thus the technique used in clinical settings. Indirect calorimeters are divided 
into two categories, open-circuit and closed-circuit. In the open-circuit indirect 
calorimeter the determinants of VO2 are the difference between inspired and expired 
O2 concentrations, and expired minute volume (Ve). In this study all the metabolic 
measurements (VO2, VCO2 and EE) will be made using an open-system indirect 
calorimeter Deltatrac®(67).  
For the measurement of spontaneously breathing patients, the subject's head is placed 
under a plastic cone (canopy) connected to the analyzer. The canopy is half-
ellipsoidal and is made of 1-mm-thick transparent PVC plastic. It is provided with 
adapters for tubing and with a wide edge of soft plastic cloth to make the construction 
airtight around the head and neck of the subject (68). The difference between Fio2 
(sampling at the entry valve of the canopy) and Feo2 is measured with a fast-response 
paramagnetic differential O2 sensor (OM-101, Datex/Instrumentarium, Helsinki, 
Finland) [69].  
The Feco2 is measured with an infrared CO2 sensor. A microcomputer controls a set 
of magnetic valves for the automatic control of the absolute Fio2, the Fico2, and gas 
analyzer baselines. VCO2 is calculated as the product of the Constant flow and the 
fraction of CO2 in the diluted expiratory flow: VCO2 = Q x F*eco2, where Q is the 
constant flow (68).  
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With the canopy, the VO2 is calculated using the Haldane transformation: VO2 = 
(Q/(1-Fio2)) x (Fio2-Feo2 - Fio2 x (Feco2-Fico2)), where Feo2 and Feco2 are the 
fractions of O2 and CO2 in the mixed expiratory gas flowing through the monitor 
(68).  EE is calculated from the measured rates of VO2 and VCO2: EE = 3.581 x VO2 
+1.448 x VCO2 - 32.4, where EE is given in kcal/day, VO2 in l/day, and VCO2 in 
l/day (70,71). Respiratory quotient is calculated as follows, RQ = VCO2/ VO2.The 
flow generator has been calibrated by burning ethanol (5 ml of 99.9 %). The monitor 
will further be calibrated using a standard gas mixture containing 95% O2 and 5% 
CO2, before each study session. 
Calorimetry is performed four times: before VLCD, before the surgical procedure (after 
VLCD) and then 3 – and 12 months post-operatively. Two of these measurements (pre-
operatively after VLCD and 3 months post-operatively) are done on the same day as PET. 
On the PET-day calorimetry is done before going into the PET-camera.  In general the 
subject is lying supine while for the measurement of spontaneously breathing, the subject's 
head is placed under a plastic cone (canopy) connected to the analyzer. Measurement lasts 
for 30 minutes (15 minutes of pre-measurements and 15 minutes actual testing). 
 
Euglycemic hyperinsulinemic clamp 
Clamp technique is a method for quantifying insulin secretion and resistance (72). In 
euglycemic hyperinsulinemic clamp, plasma insulin concentration is acutely raised and 
then gradually decreased until the final infusion speed has been achieved.  The idea is to 
block hepatic glucose production.  
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The plasma glucose concentration is kept constant at 5 mmol/l by a variable glucose 
infusion using a negative feedback principle. Under this steady-state condition of 
euglycemia, the glucose infusion rate equals glucose uptake by all the tissues in the body 
and is therefore a measure of tissue sensitivity to exogenous insulin. The more insulin 
sensitive the study subject is, the more glucose has to be infused in order to keep plasma 
glucose level constant.  
Plasma glucose is measured before clamp. Clamp-infusate is prepared individually for 
each patient according to the body surface area (BSA). BSA can be calculated as followed: 
BSA = weight0.425 (kg) * height0.725 (cm) * 0.007184. Insulin infusion is started with 
priming dose 480 ml/h for 0-4 minutes. After 4 minutes insulin infusion is changed to 240 
ml/h for 4-7 minutes. At the same time glucose infusion is started. If plasma glucose is 
normal glucose infusion rate is calculated as followed (ml/h): 0.5 * weight (kg). During 
clamp plasma glucose levels are constantly measured (every 5 minutes) and written down. 
Patient wellbeing is carefully monitored.  
After PET, insulin infusion is stopped. Glucose infusion is continued until a stable level of 
plasma glucose is achieved (healthy individuals: 6.5 mmol/l). In addition a lunch is served.  
The method of insulin-glucose clamp has been documented in detail, validated and 
described in Turku PET center’s internal method documents (METs).  
Bioimpedance 
Bioimpedance is done for the measurement of body fat content using electrical scale 
(Omron BF400). Bioimpedance is based on measuring electrical signals passing through 
the fat, lean mass and water in the body.  
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The actual impedance or conductivity of various tissues in the body is known so by 
measuring current between two electrodes and applying this information to complex 
proven scientific formulas, body composition (i.e. body fat content) can be determined. 
 
RESULTS 
 
Patient characteristics before and after surgery 
Patient grouping was based on diabetic status. Clinical and metabolic characteristics 
of the controls and non-diabetic and diabetic patients are reported in Table 1.  
At baseline, nine patients met typical diabetic clinical characteristics including higher 
fasting glucose concentrations, 2 h glucose levels in the OGTT and elevated HbA1C. 
Surgery-induced weight loss was similar in non-diabetic and diabetic groups. The 
post-operative BMI remained in the obese range. 
 
Table 1. Clinical and metabolic characteristics of the controls and non-diabetic and 
diabetic patients. 
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Whole body glucose uptake 
At baseline, obese patients were insulin resistant in the whole body as compared with 
lean controls (M value: 12.2±5.7 vs 40.3±9.5 µmol/(min*kg), p<0.001). After the 
bariatric procedure, obese patients had improved M value by 106±80%(12.2±5.7 vs 
23.3±8.1 µmol/(min*kg p<0.001) (Fig. 10). 
 
 
 
 
Fig. 10 Whole body glucose uptake 
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Skeletal muscle glucose uptake 
Insulin-mediated skeletal muscle glucose uptake in obese patients was lower than in 
lean controls (20±16.2 vs 68.4±24.7 µmol/(min*kg), p<0.001) before surgery while 
after the bariatric procedure, obese patients had improved skeletal muscle glucose 
uptake by 166±173% (20±16.2 vs 43.2±29.8 µmol/(min*kg), p<0.001). 
At baseline, nine subjects were diabetic and seven had insulin resistance (IFG and/or 
IGT) while after surgery nine have had remission of T2DM or insulin resistance, one 
improved glycemic control (T2DM vs. IFG), one worsened glycemic control (IGT vs. 
T2DM), three have maintained T2DM and two drop out from the study. 
There were no differences in fasting AT GU before (3.7±0.8 µmol/(min*kg)) or after 
surgery (5.1±6.1 µmol/(min*kg)) in obese as compared to controls (3±1.8 
µmol/(min*kg), n.s)(Fig. 11). 
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Fig. 11 Skeletal muscle glucose uptake 
Adipose tissue glucose uptake 
Insulin-mediated adipose tissue glucose uptake in obese patients was lower than in 
lean controls at baseline (5.8±2.4 vs 9.3±3.9, p<0.01). After the bariatric procedure, 
insulin-mediated adipose tissue glucose uptake was increased by 77±129% in the 
obese group (5.8±2.4 vs 9.9±5.4 µmol/(min*kg), p=0.03) (Fig. 12). 
 
 
 Fig. 12 Adipose tissue glucose uptake 
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Correlations  
There was no correlation between the delta of ATGU, muscle GU and M value after 
surgery with the delta of weight loss (n.s., for all)(Fig. 13). 
 
 Disease Remission DeltaInsEEF_ATGU 
 Correlation coefficient  (pvalue) 
DeltaInsEEF_ATGU - 0,45 (p=0,11)  
Whole body glucose uptake  0,14 (p=0,61) 
Body weight  -0,01 (p=0,94) 
 
Fig. 13 Correlations  
 
DISCUSSION 
The present data shown that bariatric surgery promotes the remission of T2DM and 
insulin resistance and this is connected with the improvement of insulin action on 
adipose tissue glucose uptake.  
At baseline, in obese patients whole body (M value: 12.2±1.14 vs 40.3±3.00 
µmol/(min*kg), p<0.001) and subcutaneous adipose tissue (5.8±0.54 vs 9.3±1.40, 
p<0.01) insulin sensitivity measured with [F-18]FDG PET was lower compared with 
healthy lean controls.  
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Moreover, skeletal muscle glucose uptake (muscle 20.0±3.24 vs 68.4±8.24 
µmol/(min*kg), p<0.001 ) measured with [F-18]FDG PET was lower in the same 
subjects.  
After the bariatric procedure, obese patients lost 23±6% of body weight.  Whole body 
(M value) and muscle and adipose tissue glucose uptake were increased by 106±80%, 
p<0.001; 166±173%, p<0.001; 77±129%, p=0.03, respectively. Furthermore, adipose 
tissue glucose uptake normalised after surgery. 
Previously, isolated adipocytes of obese individuals and patients with diabetes have 
been shown to be insulin resistant (16, 35, 36), whereas the results obtained in vivo 
have been heterogeneous (13, 14, 15). In several studies, glucose uptake per tissue 
mass was about 60% lower in obese than in lean subjects in all fat regions measured. 
Adipose tissue glucose uptake per kilogram tissue was slightly lower in abdominal sc 
areas, compared with the femoral region in the obese but not in the nonobese 
subjects. In accordance with earlier studies (1, 30, 37), the obese subjects exhibited 
skeletal muscle insulin resistance and the glucose disposal rate was decreased 
indicating whole-body insulin resistance . Moreover, the rates of whole-body glucose 
disposal correlated directly with the glucose uptake both in skeletal muscle and 
adipose tissue. 
In conclusion, the [F-18]FDG PET technique seems to be suitable for the assessment 
of metabolic events in adipose tissue regions in humans in vivo.  
At baseline, the obese subjects showed impaired whole body  and tissue specific 
glucose uptake insulin sensitivity compared to controls. 
63 
 
At baseline, nine patients had type 2 diabetes mellitus (T2DM) and seven had 
impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT). After 
surgery,  remission of T2DM or IFG / IGT was observed in ten patients. Two patients 
dropped out from the study. At baseline, obese patients had impaired whole body  (M 
value: 12.2±1.14 vs 40.3±3.00 µmol/(min*kg), p<0.001) and tissue specific (muscle 
20.0±3.24 vs 68.4±8.24 µmol/(min*kg), p<0.001 and adipose tissue 5.8±0.54 vs 
9.3±1.40, p<0.01) insulin sensitivity compared to controls.  
There were no differences in fasting adipose tissue glucose uptake before or after 
surgery in obese as compared to controls. Neither the changes in whole body nor the 
changes in tissue specific insulin sensitivity correlated with the change in weight loss. 
The remission of diabetes was positively correlated with the change produced by 
bariatric surgery on the effect of insulin on adipose tissue glucose uptake 
(Spearman´s correlation: R=0.54; p<0.05). 
In summary, the results of the present study demonstrate in humans in vivo the active 
role of the bariatric surgery in improved whole body and femoral subcutaneous 
adipose tissue insulin sensitivity. Bariatric surgery promotes the remission of type 2 
diabetes and insulin resistance. The contribution of adipose tissue to the whole-body 
insulin-stimulated glucose uptake is greater than earlier believed, and therapeutic 
interventions improving glucose disposal in adipose tissue may substantially affect 
the whole-body glucose disposal in obese subjects. 
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CONCLUSION 
Bariatric surgery promotes the remission of T2DM and insulin resistance and this is 
connected with the improvement of insulin action on adipose tissue glucose uptake.  
Improved whole body and femoral subcutaneous adipose tissue insulin sensitivity do 
not relate with the whole body weight loss. Hence, insulin sensitivity may depend on 
the intrinsic action of the bariatric surgery.  
Because  of our poor understanding of the underlying mechanisms responsible for 
insulin resistance and the lack of effective drugs for treating the condition, the need to 
discover new targets for treatment and develop novel, cost effective therapies, are 
high priorities. Therefore, understanding  this additional effect of bariatric surgery 
could lead to offers opportunities to study the molecular basis for insulin resistance 
and devise new therapies.   
The results of this thesis suggest that bariatric surgery, also called metabolic surgery, 
known to all for its effects on weight loss, in addition to making a significant weight 
loss, also results in an improvement of glycemic control in patients with type 2 
diabetes and suggest that this approach could be particularly beneficial for obese 
patients (without severely obesity) with type 2 diabetes poorly controlled with diet, 
exercise and drug therapy. 
The preliminary results described in this thesis will have to be confirmed by further 
studies; accordingly, many unanswered questions remain regarding the relative 
efficacy of bariatric surgery in patients with uncontrolled diabetes. 
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